Prediction of metaphase II oocytes according to different levels of serum AMH in poor responders using the antagonist protocol during ICSI: a cohort study

Abstract

The aim of our study was to assess the value of serum AMH in prediction of metaphase II oocytes in poor responders. We performed a prospective cohort study included 206 poor responders candidate for ICSI using antagonist protocol. They were classified into 3 groups. Group I included 50 women with AMH < 0.3 ng/ml, group II included 85 women with AMH 0.3–0.7 ng/ml and group III included 71 women with AMH > 0.7–1.0 ng/ml. The primary outcome parameter was the number of MII oocytes. There was a highly significant difference between the study groups regarding E2 at triggering (481.41 ± 222.653, 648.17 ± 264.353 and 728.74 ± 305.412 respectively, number of oocyte retrieved (2.37 ± 1.178, 3.38 ± 1.622 and 3.80 ± 1.427 respectively), number of MII oocytes (1.66 ± 1.039, 2.35 ± 1.171 and 2.61 ± 1.080 respectively), number of fertilized oocytes (1.39 ± 0.919, 1.91 ± 0.983 and 2.21 ± 0.937 respectively), , total number of embryos (1.34 ± 0.938, 1.76 ± 0.956 and 2.09 ± 0.907 respectively), clinical pregnancy rates (4.9 vs. 7.7 and 19.7% respectively). We concluded that AMH is a good predictor for number of MII oocytes in poor responders undergoing ICSI.

摘要

我们研究的目的是评估血清AMH对卵巢低反应患者MII期卵母细胞的预测价值。我们进行了一项前瞻性队列研究, 包括206名用拮抗剂方案的ICSI低反应者, 他们被分为3组, 第一组包括50名AMH<0.3 ng/ml的女性, 第二组包括85名AMH 0.3-0.7 ng/ml的女性, 第三组包括71名AMH>0.7-1.0 ng/ml的女性。主要结果参数是MII卵母细胞数目, 研究组之间在触发E2方面存在极显著差异（分别为481.41±222.653, 648.17±264.353和728.74±305.412, 取卵数（分别为2.37±1.178, 3.38±1.622和3.80±1.427）, MII卵母细胞数（分别为1.66±1.039, 2.35±1.171和2.61±1.080）, 受精卵数量（分别为1.39±0.919, 1.91±0.983和2.21±0.937）, 胚胎总数（分别为1.34±0.938, 1.76±0.956和2.09±0.907）, 临床妊娠率（分别为4.9%, 7.7%和19.7%）。我们得出结论, AMH是接受ICSI的低反应者中MII卵母细胞数量的良好预测因子。

The Chinese abstracts are translated by Prof. Dr. Xiangyan Ruan and her team: Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China.

Keywords:

• Metaphase II oocytes
• AMH
• poor responders
• antagonist protocol
• ICSI

Disclosure statement

The authors report no conflicts of interest in this work.